UroGen Pharma (URGN) option IV into data
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/27/2026
- Wall Street ends mixed as investors focus on tech earnings
- Nvidia in talks with OpenAI to guarantee $250 billion financing for data center, WSJ reports
- ASML and U.S. chip stocks sink on report of China’s DUV breakthrough
- Why is Bernstein bullish on memory stocks after Samsung, Nvidia deals?
- Oil prices settle at lowest in over a week, as US pauses attacks on Iran
- BTIG Upgrades Outlook Therapeutics Inc. (OTLK) to Buy
- Carpenter Technology CEO Brian Malloy passes; Tony Thene returns as CEO
- Applied Digital (APLD) Tops Q4 EPS by 23c, Revenue Beats
- ASML and U.S. chip stocks sink on report of China’s DUV breakthrough
- BuzzFeed cuts 35% of workforce in restructuring move
UroGen Pharma (URGN) PT Raised to $53.50 at Ladenburg Thalmann
June 14, 2024 6:54 AM EDTLadenburg Thalmann analyst Matthew Kaplan raised the price target on UroGen Pharma (NASDAQ: URGN) to $53.50 (from $48.00) while maintaining a Buy rating.
The analyst comments "UroGen disclosed strong ENVISION 12-month DoR data (82.3%) at an investor event on June 13, 2024; Rolling NDA submission expected to complete by September 2024; Potential approval as soon as 1Q25, with priority... More
Goldman Sachs Reiterates Neutral Rating on UroGen Pharma (URGN)
June 14, 2024 5:11 AM EDTGoldman Sachs analyst Paul Choi reiterated a Neutral rating and $22.00 price target on UroGen Pharma (NASDAQ: URGN).
The analyst comments "Encouraging data for UGN-102 far exceeded expectations on 12-month durability of response; focus shifting to regulatory filing and subsequent launch execution. URGN is outperforming today (+41%... More
